Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Autologous Mesenchymal Stem Cells Clear all
Not listed Phase 2 Interventional

Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis

NCT04448106
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis Shoulder
Interventions
Celltex- AdMSCs
Biological
Lead sponsor
Celltex Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 28, 2026, 1:23 PM EDT
Terminated No phase listed Observational

Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products

NCT01071577
View directory record Official record
Conditions
Bone Marrow Stromal Cells
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 28, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03355365
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Intrathecal MSC-NP injection, Intrathecal saline injection
Biological · Other
Lead sponsor
Tisch Multiple Sclerosis Research Center of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 28, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

NCT02501811
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
Mesenchymal Stem Cells (MSC), c-kit+ cells, Placebo (Plasmalyte A)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 79 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 28, 2026, 1:23 PM EDT
Withdrawn Phase 2 Interventional

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

NCT00081055
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide, cyclosporine, methotrexate, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 28, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

NCT05116540
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
HB-adMSCs, Placebo
Biological · Drug
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 28, 2026, 1:23 PM EDT
Recruiting Early Phase 1 Interventional

Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain

NCT06205342
View directory record Official record
Conditions
Chronic Pancreatitis, Chronic Pain
Interventions
Mesenchymal Stem Cells, Other: Placebo
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 28, 2026, 1:23 PM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

NCT04029896
View directory record Official record
Conditions
Cerebral Palsy
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
3 Years and older · Male only
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 28, 2026, 1:23 PM EDT
Suspended Not applicable Interventional

The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine

NCT04064879
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
AD-SVF
Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 28, 2026, 1:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cell Therapy for Early Alzheimer's Disease

NCT06775964
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
adMSC
Biological
Lead sponsor
Paul E Schulz
Other
Eligibility
60 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 28, 2026, 1:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

NCT02503280
View directory record Official record
Conditions
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions
Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System
Drug · Device
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 28, 2026, 1:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

NCT04228666
View directory record Official record
Conditions
Alzheimer Disease
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 28, 2026, 1:23 PM EDT
Not yet recruiting Phase 1 Interventional

Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

NCT06649864
View directory record Official record
Conditions
Liver Transplant; Complications, Liver Diseases
Interventions
Autologous adipose derived mesenchymal stromal cells (AMSC)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 28, 2026, 1:23 PM EDT
Suspended Phase 1 Interventional

Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury

NCT01162915
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Autologous bone marrow-derived mesenchymal stem cells.
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 28, 2026, 1:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)

NCT00587990
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Lower dose mesenchymal stem cell (MSC) injection, Placebo, Higher dose MSC injection
Biological · Genetic
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 28, 2026, 1:23 PM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

NCT04514952
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 28, 2026, 1:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease

NCT03117738
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AstroStem, Placebo-Control
Drug · Other
Lead sponsor
Nature Cell Co. Ltd.
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Costa Mesa, California • Santa Ana, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 28, 2026, 1:23 PM EDT
Not listed Phase 1 Interventional

ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion

NCT04744051
View directory record Official record
Conditions
Post-Concussion Syndrome
Interventions
50 Adipose Derived Stem Cell Infusion, 150 Adipose Derived Stem Cell Infusion, 300 Adipose Derived Stem Cell Infusion, Placebo Infusion
Drug
Lead sponsor
American CryoStem Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 28, 2026, 1:23 PM EDT
Active, not recruiting Phase 2 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients

NCT04520373
View directory record Official record
Conditions
Spinal Cord Injuries, Paralysis
Interventions
Best Medical Management: Occupational and Physical Therapy, Autologous, Adipose Derived Mesenchymal Stem Cells
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 28, 2026, 1:23 PM EDT
Not listed Phase 2 Interventional

Autologous Stem Cell Study for Adult TBI (Phase 2b)

NCT02525432
View directory record Official record
Conditions
Brain Injuries, Traumatic, Brain Injuries, Acute, TBI (Traumatic Brain Injury)
Interventions
Placebo Infusion, Autologous BMMNC Infusion
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 28, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

NCT03280056
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration
Biological · Other
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 28, 2026, 1:23 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

NCT04681118
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NurOwn (MSC-NTF cells)
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 63 Years
U.S. locations
5
States / cities
Irvine, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 28, 2026, 1:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)

NCT01087996
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Auto-hMSCs, Allo-hMSCs
Biological
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 90 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 28, 2026, 1:23 PM EDT